Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617887 | 1.00 | MEN1 (0.51) | MEN1KMT2ACYP2D6CHRNB2CHRNB4 | |
| SCHEMBL10993992 | 0.77 | TNNC1 (0.39) | HTT | |
| SCHEMBL10980430 | 0.77 | TNNC1 (0.39) | HTT | |
| SCHEMBL10993991 | 0.77 | TNNC1 (0.39) | HTT | |
| SCHEMBL10980426 | 0.77 | TNNC1 (0.39) | HTT | |
| SCHEMBL618093 | 0.76 | CHRNB2 (0.54) | CHRNB2CHRNA4GPR84RAB9AHTR2A | |
| SCHEMBL618094 | 0.76 | CHRNB2 (0.54) | CHRNB2CHRNA4GPR84RAB9AHTR2A | |
| SCHEMBL1256496 | 0.76 | CHRNB2 (0.64) | MEN1KMT2ACYP2D6CHRNB2CHRNB4 | |
| SCHEMBL1831471 | 0.76 | CHRNB2 (0.64) | MEN1KMT2ACYP2D6CHRNB2CHRNB4 | |
| SCHEMBL6961531 | 0.75 | GPR84 (0.42) | GPR84RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-10-09 | — | — | US | claimed |
| EP-1814853-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | DULL GARY M | 2006-06-08 | — | — | US | claimed |
| WO-2006053039-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9107915-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8778978-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8580826-B2 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2371818-B1 | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MUNOZ JULIO A (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2371818-A1 | Hydroxybenzoate salts of metanicotine compounds | Targacept, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090062321-A1 | Hydroxybenzoate Salts Of Metanicotine Compounds | TARGACEPT, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-7459469-B2 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1814852-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060122237-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. | 2006-06-08 | — | — | US | disclosed |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | DULL GARY M | 2006-06-08 | — | — | US | disclosed |
| WO-2006053082-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313883-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | MEN1 169/4885KMT2A 603/4885CYP2D6 302/4885 |
| US-20060122237-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | NTRK1, CHRNA10, CHRNB2 | MEN1 1491/4885KMT2A 1955/4885CYP2D6 970/4885 |
| US-20140039014-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | MEN1 171/4885KMT2A 597/4885CYP2D6 276/4885 |
| US-20120041033-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | MEN1 171/4885KMT2A 597/4885CYP2D6 276/4885 |
| US-20140288132-A1 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | MAOB, SLC6A3, HTT | MEN1 169/4885KMT2A 603/4885CYP2D6 302/4885 |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | MAOB, SLC6A3, HTT | MEN1 171/4885KMT2A 597/4885CYP2D6 276/4885 |
| US-20090062321-A1 | Hydroxybenzoate Salts Of Metanicotine Compounds | MAOB, SLC6A3, HTT | MEN1 171/4885KMT2A 597/4885CYP2D6 276/4885 |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | NTRK1, CHRNA10, CHRNB2 | MEN1 1472/4885KMT2A 1967/4885CYP2D6 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.